SAR 113945

Drug Profile

SAR 113945

Alternative Names: SAR113945

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Sanofi
  • Class Antirheumatics; Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Osteoarthritis

Most Recent Events

  • 22 Aug 2012 Sanofi completes phase I portion of its phase I/II trial in Osteoarthritis in Germany (NCT01463488)
  • 30 Apr 2012 Phase-II clinical trials in Osteoarthritis in Germany (Intra-articular)
  • 29 Mar 2012 Sanofi completes enrolment in a phase I/II trial for Osteoarthritis in Germany (NCT01463488)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top